Table 2 The clinical characteristics of SGLT2i-treated and GLP1Ra-treated patients after ATE weighting.

From: Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

 

Model A (the truncation on 99 percentiles)

Model B (the trimming by 0.05 ≦ PS ≦ 0.95)

SGLT2i (n = 501a)

GLP1Ra (n = 513a)

Standardized difference

SGLT2i (n = 338a)

GLP1Ra (n = 309a)

Standardized difference

Age (year-old)

59.7 ± 11.5

63.2 ± 12.4

0.29

62.8 ± 11.0

64.8 ± 12.4

0.17

Sex (female)

34.1 (%)

41.9 (%)

0.16

38.9 (%)

45.0(%)

0.13

BW (kg)

78.2 ± 15.9

72.7 ± 15.5

0.35

74.3 ± 14.4

71.9 ± 18.0

0.14

BMI

28.8 ± 4.8

27.5 ± 4.8

0.29

27.9 ± 4.3

27.6 ± 5.6

0.06

SBP (mmHg)

141.1 ± 13.1

142.9 ± 13.8

0.14

140.9 ± 13.5

141.1 ± 12.0

0.01

DBP (mmHg)

81.0 ± 11.3

79.0 ± 11.8

0.17

79.2 ± 11.4

76.9 ± 11.5

0.20

MAP (mmHg)

101.0 ± 9.5

100.3 ± 9.8

0.08

99.8 ± 9.6

98.3 ± 8.9

0.16

HbA1c (mmol/mol (%))

64.4 ± 14.8 (8.0 ± 1.4)

64.7 ± 15.3 (8.1 ± 1.4)

0.02

66.5 ± 16.0 (8.2 ± 1.5)

65.8 ± 16.3 (8.2 ± 1.5)

0.04

eGFR (mL/min/1.73m2)

76.4 ± 21.6

72.9 ± 22.0

0.16

71.0 ± 19.9

69.3 ± 22.0

0.08

LnACR

1.66 ± 0.67

1.62 ± 0.68

0.06

1.67 ± 0.71

1.65 ± 0.82

0.03

Duration of the treatment (month)

33.4 ± 10.7

35.3 ± 25.7

0.10

36.4 ± 9.6

37.9 ± 21.9

0.09

The concomitant treatment

SU

25.5 (%)

25.2 (%)

0.01

18.4 (%)

21.4 (%)

0.08

Metformin

55.1 (%)

56.1 (%)

0.02

46.6 (%)

45.0 (%)

0.03

Insulin

29.7 (%)

34.1 (%)

0.09

40.2 (%)

41.4 (%)

0.02

Pioglitazone

17.6 (%)

9.4 (%)

0.24

15.1 (%)

13.6 (%)

0.04

RAS inhibitor

58.7 (%)

63.2 (%)

0.09

63.6 (%)

58.9 (%)

0.10

CCB

48.6 (%)

47.3 (%)

0.03

50.0 (%)

51.8 (%)

0.04

β blocker

16.1 (%)

15.0 (%)

0.03

20.8 (%)

22.1 (%)

0.03

Diuretics (loops and thiazides)

6.6 (%)

6.6 (%)

0.003

7.4 (%)

7.4 (%)

0.003

Statin

57.2 (%)

52.2 (%)

0.10

55.2 (%)

52.4 (%)

0.05

  1. Values represent the mean ± standard difference, or n (n/total %).
  2. ATE average treatment effect, BMI body mass index, BW body weight, CCB calcium channel blocker, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, GLP1Ra glucagon-like-1 receptor agonist, HbA1c glycated hemoglobin A1c, LnACR logarithmic value of urine albumin-to-creatinine ratio, MAP mean arterial pressure, PS propensity score, RAS renin aldosterone system, SBP systolic blood pressure, SGLT2i sodium glucose cotransporter inhibitor, SU sulfonylurea.
  3. aCalculated number of participants after weighting.
Back to article page